Positive early data from observational study of siltuximab in the treatment of SARS-CoV-2 infection

The SISCO study has enrolled 25 patients with respiratory complications. According to interim data from the first 21 patients followed up for 7 days, 33% experienced clinical improvement (reduced need for oxygen support) and 43% saw their condition stabilise.

SPS commentary:

Siltuximab is approved for the treatment of adults with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. It is currently under investigation for patients with SARS-CoV-2 infection who have developed serious respiratory complications.

PharmaTimes